28,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
As the only central nervous system tissue that can be directly imaged non-invasively using widely available technology, the retina offers a uniquely accessible window into the brain. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic metabolic diseases, including Type 2 Diabetes, hypertension, non-alcoholic fatty liver disease (NAFLD), prostate enlargement, musculoskeletal joint friction, cardiac arrhythmias, neurodegenerative waste accumulation (Alzheimer's), and elevated intraocular hydraulic pressure (glaucoma), are frequently treated as distinct, unavoidable consequences of chronological aging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Forty-eight studies, mostly of weak- or moderate-quality, met inclusion criteria. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component. 3 key findings →
Design: meta-analysis Participants: 213,604 Evidence: high
Full summary, score breakdown and related studies → Original source
These findings reinforce the potential of GLP-1RAs and SGLT2i as therapeutic options to slow cognitive decline in DM2, possibly depending on glycemic control and central modulation. 5 key findings →
Design: cohort study Participants: 12 Evidence: high
Full summary, score breakdown and related studies → Original source
Among adults with obesity or overweight with a weight related condition, there was no difference in the risk of PD or Parkinsonian disorders between GLP-1 RA users and non-users. 4 key findings →
Design: cohort study Participants: 11,683 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Eligible studies reported MACE or dementia outcomes in adults ≥ 50 years for at least one of three intervention classes (RZV, SGLT2i, GLP-1 RA) versus placebo or active comparator, with follow-up ≥ 6 months. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Our findings confirm the diagnostic value of urinary β-amyloid protein detection in MCI and AD-related dementia. 5 key findings →
Design: case-control study Participants: 51,187 Evidence: high
Full summary, score breakdown and related studies → Original source
Long-term metformin treatment is associated with a reduced risk of dementia and better memory performance among persons with pre-diabetes or T2D. Longer follow-up with more dementia cases is needed to confirm our findings. 5 key findings →
Design: longitudinal study Participants: 1,483 Evidence: high
Full summary, score breakdown and related studies → Original source
Among 2,577,000 Veterans (mean age, 63 years; 4.5% female; 65% White; 15% Black), 10% initiated ARBs and 90% initiated ACEIs. 5 key findings →
Design: longitudinal study Participants: 2,577,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We investigated brain, inflammation, cardiometabolic, and gut health changes associated with a six-month multidomain lifestyle intervention in Dutch older adults at risk for cognitive decline and dementia. 5 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source
AD prevention must transcend the "geriatric disease" mindset. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This provides the first evidence in older adults with cognitive concerns that higher step counts are associated with fewer depressive but more anxiety symptoms. 5 key findings →
Design: randomized controlled trial Participants: 629 Evidence: high
Full summary, score breakdown and related studies → Original source
Polygenic scores summarise genetic predisposition to a trait, but a population-level accuracy figure cannot tell a clinician whether a given prediction is reliable for the person in front of them. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Greater diversity of social participation was associated with better long-term cognitive maintenance among older adults with hypertension and/or diabetes. 5 key findings →
Design: longitudinal study Participants: 547 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Recruitment (88.0%) and protocol fidelity (100%) met or exceeded prespecified progression criteria, whereas retention and follow-up data availability were 59.1% (13/22), slightly below the predefined 60% criterion. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Forty participants completed the study (intervention, n = 21; control, n = 19). 4 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is the main cause of death and disability in the United States in people younger than 35 years old and is a common cause of wartime injuries. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Multidomain interventions have small but consistent beneficial effects on cognitive measures, suggesting the potential to reduce cognitive impairment and dementia risk. 3 key findings →
Design: systematic review Participants: 23,209 Evidence: high
Full summary, score breakdown and related studies → Original source
Insomnia disorder affects approximately 10–20% of adults and is usually chronic. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Of total 8,321 participants, 24.88% (2,070) developed cognitive impairment during a 10-year follow-up. 5 key findings →
Design: longitudinal study Participants: 8,321 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Specific disease clusters involving diabetes, oral disease, sensory impairment, and osteoporosis were associated with suspected dementia and neuropsychiatric heterogeneity, supporting integrated multimorbidity-oriented screening and care. 4 key findings →
Participants: 2,597 Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injuries (TBIs) are associated with increased risk of neurodegenerative disease, including Alzheimer’s disease (AD); however, the mechanisms by which TBI promotes AD pathogenesis remain poorly understood. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These findings indicate that the cognitive impact of hearing loss depends on structural resources, highlighting the need to integrate sensory health and social context in dementia prevention efforts. 5 key findings →
Participants: 2,397 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings reveal marked geographic variation in dementia risk factors, highlighting the need for region-specific prevention strategies. 4 key findings →
Participants: 40,000 Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 3,795 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,980 records, built mostly from automated pulls of Europe PMC (62.8% of the library) and OpenAlex (17.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,038 records (3.6% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →